Dr. Sami G. Diab, MD

Dr. Diab practices at Pagosa Springs Medical Center in Pagosa Springs, Colorado, part of Pagosa Springs Medical Center.

Dr. Diab's NPI, 1548244270, was assigned on December 6, 2005. Dr. Diab holds Colorado license 37758.

Dr. Diab's primary practice is Pagosa Springs Medical Center, at 95 S Pagosa Blvd, Pagosa Springs, CO 81147 in Archuleta County. The practice phone is (970) 731-3700.

Dr. Diab's primary practice is Pagosa Springs Medical Center in Pagosa Springs, Colorado, part of Pagosa Springs Medical Center. Dr. Diab is also affiliated with Saint Joseph Hospital. The medical group on file is Pagosa Springs Medical Center. Dmand AI also links Dr. Diab to 3 more hospitals and 3 medical groups, each named with a free account. Dr. Diab's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Diab practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Diab's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Diab is licensed in Colorado.

CMS data shows 243 Medicare services from Dr. Diab across 5 procedure codes in 2024, all of them office visits, for 122 Medicare patients. Medicare paid $17,349 for them.

CMS counts 122 Medicare patients who saw Dr. Diab in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have cancer, and 70% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Diab's median patient age at 70, with 61% women.

In 2024, Dr. Diab wrote 326 Medicare Part D claims for 69 patients. 78% of them were for generic drugs. CMS names the drug for 128 of them, across 8 drugs with 11 or more claims each, at $39,644 in total drug cost. In 2023, CMS named 256 claims across 10 drugs.

Dr. Diab accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Diab, published from 2013 to 2023. 2019 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Breast Neoplasms. Dr. Diab's most frequent co-authors are Sara A. Hurvitz, MD, Joyce Ann O'Shaughnessy, MD and Paul D. Richards, MD.

Dmand AI links Dr. Diab to 9 clinical trials, 4 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Triple Negative Breast Neoplasms and Ovarian Neoplasms. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Diab that name 1 trial.

CMS Open Payments shows 307 general payments to Dr. Diab from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. Pfizer Inc. paid the most, $74,845. It also lists 5 research payments totaling $5,730 from 2018 to 2020, naming 1 clinical trial.